RxDoctor Payments Data

Helge Hartung

Pediatric Hematology-Oncology · Philadelphia, PANPI 1790839330

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Genentech USA, Inc. at 35.8% of the total. That places this record below the midpoint for pediatric hematology-oncology clinicians in PA, where the typical reported total is $252.

$70in general payments, 2019–2025

Across 3 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$25
  • Biogen$24
  • Acadia Pharmaceuticals Inc$20
$660,568in research payments, 2019–2025

Across 35 payments — averaging $18,873 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$365K
  • Global Blood Therapeutics, Inc.$296K

What the payments were for

  • Food & beverage$70100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$70 in reported general payments places this provider in the 30th percentile of 139 pediatric hematology-oncology providers in Pennsylvania.

See all pediatric hematology-oncology providers in Pennsylvania

Other pediatric hematology-oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →